Crescent Grove Advisors LLC Cuts Stake in Pfizer Inc. (PFE)
Tweet
Crescent Grove Advisors LLC lessened its position in shares of Pfizer Inc. (NYSE:PFE) by 12.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,252 shares of the biopharmaceutical company’s stock after selling 3,571 shares during the quarter. Crescent Grove Advisors LLC’s holdings in Pfizer were worth $932,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Earnest Partners LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $105,000. First Dallas Securities Inc. acquired a new position in shares of Pfizer during the fourth quarter valued at $118,000. Woodard & Co. Asset Management Group Inc. ADV acquired a new position in shares of Pfizer during the fourth quarter valued at $118,000. Delpha Capital Management LLC acquired a new position in shares of Pfizer during the fourth quarter valued at $126,000. Finally, Americafirst Capital Management LLC acquired a new position in shares of Pfizer during the third quarter valued at $127,000. 69.44% of the stock is currently owned by institutional investors and hedge funds. Get Pfizer alerts:
In other Pfizer news, EVP Laurie J. Olson sold 19,000 shares of the stock in a transaction dated Wednesday, June 6th. The stock was sold at an average price of $36.45, for a total value of $692,550.00. Following the completion of the sale, the executive vice president now directly owns 98,644 shares in the company, valued at $3,595,573.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink . Also, CEO Ian C. Read sold 132,312 shares of the stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total value of $4,764,555.12. The disclosure for this sale can be found here . Insiders sold 156,535 shares of company stock valued at $5,647,222 over the last 90 days. Corporate insiders own 0.06% of the company’s stock.
Several equities analysts have recently issued reports on PFE shares. Credit Suisse Group set a $39.00 price target on Pfizer and gave the company a “neutral” rating in a research note on Monday, June 11th. Jefferies Financial Group set a $38.00 target price on Pfizer and gave the company a “hold” rating in a research note on Friday, April 13th. BMO Capital Markets set a $43.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, March 6th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, April 12th. Finally, Barclays lowered Pfizer from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $41.00 to $38.00 in a research note on Thursday, April 5th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $40.27.
Shares of Pfizer opened at $36.21 on Thursday, Marketbeat Ratings reports. Pfizer Inc. has a 1 year low of $32.32 and a 1 year high of $39.43. The stock has a market capitalization of $216.57 billion, a price-to-earnings ratio of 13.66, a price-to-earnings-growth ratio of 1.81 and a beta of 0.91. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.45.
Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The company had revenue of $12.91 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same period in the prior year, the company earned $0.69 earnings per share. The company’s revenue for the quarter was up 1.0% compared to the same quarter last year. research analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, June 1st. Shareholders of record on Friday, May 11th were issued a $0.34 dividend. The ex-dividend date of this dividend was Thursday, May 10th. This represents a $1.36 annualized dividend and a dividend yield of 3.76%. Pfizer’s dividend payout ratio (DPR) is currently 51.32%.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE). Pfizer Pfizer
The post Crescent Grove Advisors LLC Cuts Stake in Pfizer Inc. (PFE) appeared first on Denny Boy’s Interesting Blog.
from Denny Boy’s Interesting Blog https://ift.tt/2tIZkEZ via Article Source
from Tumblr https://ift.tt/2lN78Bk
No comments:
Post a Comment